The PML nuclear bodies: actors or extras?
The PML and SP100-containing nuclear bodies (NBs) represent the best-studied example of a defined nuclear substructure the integrity of which is compromised in certain human diseases, including leukemia, neurodegenerative disorders and viral infection. Although recent progress has underscored the unexpectedly broad involvement of NB constituents in the control of cell growth, gene regulation and apoptosis in both pathological and normal contexts, evidence for a specific physiological activity within the NBs remains scant, thus precluding a unifying hypothesis for NB function.
Seeler
J S
JS
Unité de Recombinaison et Expression Génétique INSERM U163 Institut Pasteur 28 rue du Docteur Roux, 75724, Paris, Cedex 15, France.
Dejean
A
A
D017209:Apoptosis / Q000235:genetics; D002455:Cell Division / Q000235:genetics; D002467:Cell Nucleus / Q000378:metabolism* / Q000648:ultrastructure; D002843:Chromatin / Q000502:physiology; D005786:Gene Expression Regulation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D025842:SUMO-1 Protein; D020754:Spinocerebellar Ataxias / Q000235:genetics; D014158:Transcription, Genetic; D014452:Ubiquitins / Q000378:metabolism
D002843:Chromatin; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D025842:SUMO-1 Protein; D014452:Ubiquitins; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein